• 1
    Perou CM,Sorlie T,Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747752.
  • 2
    Sorlie T,Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 1086910874.
  • 3
    Sorlie T,Tibshirani R,Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 84188423.
  • 4
    Nielsen TO,Hsu FD,Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 53675374.
  • 5
    Foulkes WD,Brunet JS,Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004; 64: 830835.
  • 6
    Haffty BG,Yang Q,Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24: 56525657.
  • 7
    Harris LN,Broadwater G,Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8: R66.
  • 8
    Tsuda H,Takarabe T,Hasegawa F, et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol. 2000; 24: 197202.
  • 9
    Barnholtz-Sloan JS,Sloan AE,Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22: 28652872.
  • 10
    Albiges L,Andre F,Balleyguier C, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol. 2005; 16: 18461847.
  • 11
    Carey LA,Perou CM,Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 24922502.
  • 12
    Foulkes WD,Stefansson IM,Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003; 95: 14821485.
  • 13
    Nanda R,Hu Z,He X, et al. Characterization of aggressive breast cancer in African American and Caucasian women: patterns of gene expression in primary breast tumors. J Clin Oncol. 2004; 22: 838s. Abstract 9513.
  • 14
    Hicks DG,Short SM,Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006; 30: 10971104.
  • 15
    Bendell JC,Domchek SM,Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003; 97: 29722977.
  • 16
    Lin NU,Bellon JR,Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004; 22: 36083617.
  • 17
    Lin NU,Carey LA,Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol. 2006; 24: 3s.
  • 18
    Cox DR. Regression models and life tables. J R Stat Soc [B]. 1972; 34: 187202.
  • 19
    SAS Institute Inc. SAS/STAT User's Guide. 4th ed. Cary, NC: SAS Institute; 1989.
  • 20
    Burstein HJ,Parker LM,Savoie J, et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat. 2002; 76(1 suppl). Abstract 446.
  • 21
    Burstein HJ,Spigel D,Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat. 2005; 94: S6. Abstract 4.
  • 22
    Miller K,Wang M,Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 26662676.
  • 23
    Chia SK,Speers CH,D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007; 110: 973979.
  • 24
    Tsukada Y,Fouad A,Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983; 52: 23492354.
  • 25
    Lin NU,Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007; 13: 16481655.
  • 26
    Fulford LG,Reis-Filho JS,Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007; 9: R4.
  • 27
    Clayton AJ,Danson S,Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004; 91: 639643.
  • 28
    Altaha R,Crowell E,Ducatman B, et al. Risk of brain metastases in HER2/neu-positive breast cancer. J Clin Oncol. 2004; 22: 47s.
  • 29
    Pestalozzi BC,Zahrieh D,Price KN, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006; 17: 935944.
  • 30
    Stemmler HJ,Schmitt M,Harbeck N, et al. Application of intrathecal trastuzumab (Herceptin trade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep. 2006; 15: 13731377.
  • 31
    Burstein HJ,Lieberman G,Slamon DJ, et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005; 16: 17721777.
  • 32
    Kirsch DG,Ledezma CJ,Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol. 2005; 23: 21142116; author reply, 2116–2117.
  • 33
    O'Meara WP,Seidman AD,Yamada Y, et al. Impact of HER2 status in breast cancer patients receiving stereotactic radiosurgery for brain metastases. J Clin Oncol. 2005; 23: 37s.
  • 34
    Gori S,Rimondini S,DeAngelis V, et al. Central nervous system metastases in HER–2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist. 2007; 12: 766773.
  • 35
    Tham YL,Sexton K,Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006; 107: 696704.
  • 36
    Nam BH,Kim SY,Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008; 10: R20.
  • 37
    Franco A,Col N,Chlebowski RT. Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis. J Clin Oncol. 2004; 22: 12s. Abstract 539.
  • 38
    Lower EE,Glass E,Blau R, et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat. 2008 Feb 14 [Epub ahead of print].